# ECO Animal Health Group PBT increased significantly to £20.3m

- Link: https://www.directorstalkinterviews.com/eco-animal-health-group-pbt-increased-significantly-to-20.3m/4121011735
- Published: 2021-07-26T07:10:27+01:00
- Author: Giles

**ECO Animal Health Group plc** (LON:EAH) have today provided results for the year
ended 31st March 2021.

**HIGHLIGHTS**

**Financials**

·      Sales up 46% at £105.6m (2020: £72.1m)

·      Gross margin increased to 51% (2020: 46%)

·      Profit before tax increased significantly to £20.3m (2020 restated: £6.1m)

·      Earnings per share increased significantly to 12.08p (2020 restated: 5.77p)

·      Cash generated from operations significantly stronger at £15.8m (2020: £5.5m)

·      Net cash at the end of the period £19.5m (2020: £9.8m)

·      New product development expenditure 17% lower at £9.1m (2020: £10.9m)

·      Dividend re-introduced – 1p per share (2020: Nil)

**Operations**

·      Aivlosin® demand increased by 44% led by

o  Rapid recovery & return to profitability in China as swine herds rebuilt following
worst effects of African Swine Fever (ASF)

o  Strong growth in USA amid domestic demand & strengthening exports

o  Strong export driven growth in Brazil

·      Aivlosin® water soluble formulation approval in pigs for _M. hyopneumoniae_
granted in USA, Canada & EU

·      First vaccine licence approval in Brazil

·      Two worldwide exclusive research partnerships signed to develop & licence
novel vaccines for pigs against Porcine Respiratory & Reproductive Syndrome virus(
PRRSV)

·      Business logistics, volumes and access uninterrupted during COVID-19 remote
working

> **Marc Loomes, CEO of ECO Animal Health Group plc, commented:** “These excellent
> results reflect the strong recovery in selected key markets which, together with
> the adaptability and innovation shown by our employees has delivered a record 
> result during a year of formidable operational challenges arising from macroeconomic
> events.  We are excited about the progress within our new product development 
> programmes, with previous announcements demonstrating the potential of our in-
> house science and external collaborations.  This year has had a solid start, we
> carefully monitor the demand for our products and recognise the easing in China,
> but remain confident of a successful out-turn for the year.”

Share on:
